



Regulação e Avaliação do Medicamento e Produtos de Saúde

1st Part 3rd May

17h00 – 18h30

Challenges for the Approval and Reimbursement of Anti-Cancer Immunotherapeutic Drugs

- Mira Pavlovic-Ganascia (NDA)

18h30 – 20h00

The EUnetHTA Framework: state of play, challenges and future goals

- Rui Santos Ivo (ULisboa, INFARMED IP, EMA MB)

4th May

9h00 - 10h30

Biosimilars: when a copy is not a copy

- Fátima Ventura (ULisboa, INFARMED IP, CHMP Alternate Member)

10h30 – 12h00

Challenges and Opportunities for Paediatric Drug Development

- Koenrad Norga (Vice-Chair of PDCO, CHMP Member, Leuven University / Belgium)

14h00 – 15h30

Cardiovascular Outcome Trials: a regulatory conundrum

- Bart van der Schueren (Leuven University, Belgium / CHMP Member)

15h30 – 17h00

Strengths and Weaknesses of the European Regulatory Framework: perspectives from a stakeholder

- Karsten Bruins-Slot (Roche, Norway; Former-CHMP Member Norway)

Registration at www.ff.ulisboa.pt



